•
Dec 31, 2023

Allogene Q4 2023 Earnings Report

Allogene reported financial results and provided a corporate update for Q4 2023.

Key Takeaways

Allogene Therapeutics ended 2023 with $448.7 million in cash, cash equivalents and investments and anticipates its cash runway will fund operations into 2026. Start-up activities for the ALPHA3 trial are underway and the trial is expected to begin in mid-2024. Initial data readout from Phase 1 ALPHA2 CLL cohort (n=12) is projected by year-end 2024. ALLO-329 is expected to enter Phase 1 clinical trials in early 2025.

Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL): Start-Up Activities Underway; Enrollment to Begin Mid-2024

Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Data Projected YE 2024

ALLO-329 in Autoimmune Disease (AID): Differentiated Next-Generation CD19 Dagger® Program Designed for AID will Focus on Eliminating Lymphodepletion and Meeting Demand; Phase 1 Clinical Trials in Early 2025

Ended 2023 with $448.7 Million in Cash, Cash Equivalents and Investments; Reiterates Cash Runway Projection into 2026

Total Revenue
$21K
Previous year: $47K
-55.3%
EPS
-$0.43
Previous year: -$0.66
-34.8%
Gross Profit
-$54.6M
Previous year: -$3.26M
+1575.6%
Cash and Equivalents
$449M
Previous year: $576M
-22.2%
Free Cash Flow
-$53.9M
Previous year: -$63.8M
-15.5%
Total Assets
$643M
Previous year: $817M
-21.3%

Allogene

Allogene

Allogene Revenue by Segment

Forward Guidance

The Company expects a decrease in cash, cash equivalents, and investments of approximately $190 million in 2024. Based on current assumptions, the Company continues to expect its cash runway to fund operations into 2026. GAAP Operating Expenses are expected to be approximately $280 million, including estimated non-cash stock-based compensation expense of approximately $60 million. These estimates exclude any impact from potential business development activities.

Positive Outlook

  • Cash runway to fund operations into 2026.
  • GAAP Operating Expenses are expected to be approximately $280 million.
  • Estimated non-cash stock-based compensation expense of approximately $60 million.
  • Start-up activities for the ALPHA3 trial are underway and the trial is expected to begin in mid-2024.
  • ALLO-329 is expected to enter Phase 1 clinical trials in early 2025.

Challenges Ahead

  • The Company expects a decrease in cash, cash equivalents, and investments of approximately $190 million in 2024.
  • Estimates exclude any impact from potential business development activities.
  • Net loss for the fourth quarter of 2023 was $85.8 million
  • ALPHA3 trial will initially test two lymphodepletion regimens (one with standard fludarabine and cyclophosphamide plus ALLO-647 and one without ALLO-647).
  • One lymphodepletion arm will be discontinued following a planned interim analysis in mid-2025 designed to select the most appropriate regimen for this patient population.